5 Best Mid Cap Stocks To Own For 2015

Lawyers representing the city of Detroit outside of bankruptcy court.

NEW YORK (CNNMoney) The first six months of Detroit’s bankruptcy case cost taxpayers $36 million in fees and expenses for lawyers and consultants, according to a court filing late Tuesday.

The report by the independent fee examiner accounts for costs incurred from the city’s initial filing on July 18, 2013 through the end of last year. The city spent $13 million during the first three months of the proceedings, and Tuesday’s filing shows bills from lawyers and other consultants jumped 61% in the last quarter of the year.

The city’s fee examiner Robert Fishman said in his report that the costs, while substantial, were reasonable and in line with the complexity and quality of the services provided.

5 Best Mid Cap Stocks To Own For 2015: ONEOK Partners L.P.(OKS)

ONEOK Partners, L.P. engages in the gathering, processing, storage, and transportation of natural gas in the United States. The company?s Natural Gas Gathering and Processing segment gathers and processes natural gas produced from crude oil and natural gas wells located in the Mid-Continent region; and gathers natural gas in the Williston Basin, which spans portions of Montana and North Dakota, and the Powder River Basin of Wyoming. Its Natural Gas Pipelines segment primarily owns and operates regulated natural gas transmission pipelines, natural gas storage facilities, and natural gas gathering systems for non-processed gas. It also provides interstate natural gas transportation and storage services. This segment?s interstate natural gas pipeline assets transport natural gas through FERC-regulated interstate natural gas pipelines in North Dakota, Minnesota, Wisconsin, Illinois, Indiana, Kentucky, Tennessee, Oklahoma, Texas, and New Mexico. In addition, it transports intra state natural gas through its assets in Oklahoma; and owns underground natural gas storage facilities in Oklahoma, Kansas, and Texas. Its Natural Gas Liquids segment gathers, fractionates, and treats natural gas liquids (NGLs), as well as stores NGL products primarily in Oklahoma, Kansas, and Texas. This segment owns FERC-regulated natural gas liquids gathering and distribution pipelines in Oklahoma, Kansas, Texas, Wyoming, and Colorado; terminal and storage facilities in Missouri, Nebraska, Iowa, and Illinois; and FERC-regulated natural gas liquids distribution and refined petroleum products pipelines in Kansas, Missouri, Nebraska, Iowa, Illinois, and Indiana that connect its Mid-Continent assets with Midwest markets, including Chicago, Illinois. ONEOK Partners GP serves as the general partner of the company. The company was formerly known as Northern Border Partners, L.P. and changed its name to ONEOK Partners, L.P. in May 2006. The company was founded in 1993 and is base d in Tulsa, Oklahoma.

Advisors’ Opinion:

  • [By Paul Ausick]

    Large MLPs with geographically diversified operations will fare better because they can shift assets around and make sure that all their distribution-paying subsidiaries meet the payroll, so to speak. Here are the seven largest MLPs by market cap:

    Enterprise Product Partners LP (NYSE: EPD) – $61.23 billion Kinder Morgan Energy Partners LP (NYSE: KMP) – $35.13 billion Williams Partners LP (NYSE: WPZ) – $21.95 billion Plains All American Pipeline LP (NYSE: PAA) – $19.3 billion Energy Transfer Partners LP (NYSE: ETP) – $17.78 billion Magellan Midstream Partners LP (NYSE: MMP) – $15.52 billion Oneok Partners LP (NYSE: OKS) – $12.95 billion

    Size is not the only thing that matters, but size can help overcome some of the cash flow issues these MLPs face. The differentiating factor is a company’s distribution coverage ratio which is the cash the MLP has to distribute to its limited partners divided by its maintenance capex and interest on the company’s debt. Anything number larger than 1 is solid.

  • [By Lauren Pollock]

    Oneok Partners LP(OKS) issued guidance for 2014 that surpasses its estimate for the current year, citing growth in natural-gas volumes.

    QEP Resources Inc.(QEP) plans to separate its midstream business, QEP Field Services Co., into a separate entity, including its interest in QEP Midstream Partners LP(QEPM).

  • [By David Dittman]

    Answer: ONEOK is running wild in anticipation of its completion of transactions that will make it essentially a general partner, with interests in ONEOK Partners LP (NYSE: OKS) and the soon-to-be-spun-out ONE Gas Inc (NYSE: OGS). ONEOK already has an admirable record of dividend growth, and these moves will drive acceleration in 2014 payout growth.

5 Best Mid Cap Stocks To Own For 2015: Latteno Food Corp (LATF)

Latteno Food Corp. (Latteno), incorporated on August 24, 1994, is engaged in acquiring, organizing, developing and upgrading companies in the international food and beverage market. Latteno is specializing in the dairy industry and coffee industry. The Company operates through its subsidiary in Brazil. On February 10, 2010 Latteno acquired Global Milk Businesses and Administration of Private Properties Ltda. (Global Milk). Global Milk holds the rights of certain intellectual property of the brand name products manufactured and sold under the brand name Teixeira. In March 2013, the Company acquired Green Cannabis Collective Inc.

Latteno is leasing an instant and roasted coffee factory located in Cruzeiro, Sao-Paulo, which was property the Company previously owned under its BDFC Brasil Alimentos Ltda (BDFC) subsidiary. In addition to the lease, the Company has maintained ownership of four brand names, Samba Cafe, Vivenda, Torino and Brazilian Best, used in the p ast by Latteno to sell its instant and roasted coffee across the world. The Company engaged the service companies to assist with its operations, such as Log-Frio Ltda, SigaSolutions Ltda, Microsiga Ltda and Varistao Transportes Ltda.

The Company competes with Nestle, Companhia Cacique de Cafe Soluvel, Cafe Soluvel Brasilia and Companhia lguacu de Cafe Soluvel.

Advisors’ Opinion:

  • [By James E. Brumley]

    A week and a half ago when I suggested Latteno Food Corp. (OTCMKTS:LATF) was an effective way of getting into the medical marijuana craze for anyone who missed the big runups (the first or the second time) from names like Medical Marijuana Inc. (OTCMKTS:MJNA) or Hemp, Inc. (OTCMKTS:HEMP), not many people agreed with my assessment. That’s the nice way of saying I received some “colorful counter-opinions” to my bullishness on LATF. Indeed, some readers were downright enraged I would dare compare the company to stocks like MJNA or HEMP, citing reasons ranging from the possibility that it’s a complete scam to the possibility that the capital structure as amazingly unfair to current shareholders.

  • [By James E. Brumley]

    What do you get when you cross a Coffee Holding Co., Inc. (NASDAQ:JVA) with a Medical Marijuana Inc. (OTCMKTS:MJNA) and a Kraft Foods Group Inc. (NASDAQ:KRFT)? No, it’s not a setup for a punch line – there’s a legitimate answer. And that answer is, Latteno Food Corp. (OTCMKTS:LATF).

  • [By James E. Brumley]

    What do you get when you cross a Coffee Holding Co., Inc. (NASDAQ:JVA) with a Medical Marijuana Inc. (OTCMKTS:MJNA) and a Kraft Foods Group Inc. (NASDAQ:KRFT)? No, it’s not a setup for a punch line – there’s a legitimate answer. And that answer is, Latteno Food Corp. (OTCMKTS:LATF).

5 Best Mid Cap Stocks To Own For 2015: Seaspan Corporation(SSW)

Seaspan Corporation owns and operates the containerships that are engaged in the deep-sea container transportation business in Hong Kong. The company charters its containerships pursuant to long-term, fixed-rate time charters to various container liner companies. As of December 31, 2009, it owned and operated a fleet of 42 containerships. The company was incorporated in 2005 and is headquartered in Majuro, the Marshall Islands.

Advisors’ Opinion:

  • [By Jack Adamo]

    Predictably, Seaspan (SSW) suffered a big drop in normalized EPS for 2013, due to the conversion of all its Class A preferred stock to common stock, plus another secondary common stock offering, which, together, increased the common stock share count by 33%.

  • [By Dan Caplinger]

    The stock market suffered another up-and-down day, again finishing on the losing end as investors saw their fear levels rise dramatically after the Fed’s latest minutes were released. With less clarity than ever about the Fed’s eventual plans to end its quantitative easing program, investors are justifiably concerned. But big losses for Seaspan (NYSE: SSW  ) , voxeljet (NYSE: VJET  ) , and Direxion Daily Gold Miners Bull 3x (NYSEMKT: NUGT  ) showed how vulnerable some investments are to the uncertainty. Let’s look more closely at what happened to push these share prices down.

  • [By Lauren Pollock]

    Seaspan Corp.(SSW) said it plans to offer 3.5 million Class A common shares, and expects to use the proceeds from the offering for general corporate purposes, which may include funding vessel acquisitions. The containership owner recently had about 64.9 million shares outstanding, according to FactSet. Shares fell 8% to $21.55 premarket.

5 Best Mid Cap Stocks To Own For 2015: Perrigo Company PLC (PRGO)

Perrigo Company plc, incorporated on March 23, 1988, is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri. The Company’s businesses include Consumer Healthcare, Nutritionals, Rx Pharmaceuticals, API, Life Sciences and Other Businesses. The Company offers Healthcare Products across a range of product categories primarily in the United States, the United Kingdom, Mexico, Israel and Australia, and distributes into dozens of other markets worldwide, including Canada, China and Latin America. In February 2014, the Company announced that it has acquired a basket of value-brand OTC products sold in Australia and New Zealand from Aspen Global Inc.

The Company operates through several wholly ow ned subsidiaries. In the United States, its operations are conducted primarily through L. Perrigo Company, Perrigo Company of South Carolina, Inc., Perrigo New York, Inc., PBM Products, LLC, PBM Nutritionals, LLC, Paddock Laboratories, LLC, Perrigo Diabetes Care, LLC (formerly CanAm Care, LLC), Sergeant’s Pet Care Products, Inc. and Fidopharm, Inc. Outside the United States, its operations are conducted primarily through Perrigo Israel Pharmaceuticals Ltd., Chemagis Ltd., Quimica y Farmacia S.A. de C.V., Laboratorios Diba, S.A., Wrafton Laboratories Limited, Galpharm Healthcare Ltd., Orion Laboratories Pty Ltd and Rosemont Pharmaceuticals Ltd.

Consumer Healthcare

Perrigo Consumer Healthcare (CHC) operation includes the Company’s United States, United Kingdom and Mexico manufacturing operations supporting the sale of OTC pharmaceutical products. Perrigo CHC supplies more than 15 categories and 500 formulas and offers analgesics, cough and cold remedi es, and gastrointestinal and feminine hygiene products, as w! ell as vitamins, dietary supplements and nutritional drinks. Perrigo offers a range of products, such advertised brand products as Tylenol, Advil or One-A-Day. Tylenol has acetaminophen as an active ingredient and is available in stores’ analgesic (pain reliever) aisle. Store-brand acetaminophen is located next to the national brand, offering the same active ingredient (acetaminophen) and the same pain relief.

Perrigo Nutritionals

Perrigo is a manufacturer of nutrition products for the store brand market. Nutrition products include infant formula, pediatric nutritionals and vitamins, minerals, and supplements. Acquired by Perrigo, Perrigo Nutritionals, formerly PBM Products, LLC, had introduced private-label, or store-brand infant formulas to the United States. Perrigo Nutritionals is the supplier of store-brand infant formulas and nutrition products. With distribution to major retailers, Perrigo Nutritional products can be found in more than 40,000 retail locations around the world. Its pediatric nutritionals business extends its offerings to children well beyond infancy. Its baby cereals, toddler foods, and pediatric nutritional drinks are available as store brands at various retail locations throughout the United States and the international community. Perrigo manufactures a range of vitamins, minerals, and supplements, in every major segment of the business. Marketed under the store brand labels of the retailers in the food, drug, mass-merchandise and wholesale club channels, it manufactures over 395 formulas of dietary supplements. Its brands include Centrum, One-A-Day, Flintstones, and Osteo-Bi-Flex.

Rx Pharmaceuticals

The Company’s Rx Pharmaceuticals business is focused on the development, manufacture and sale of generic prescription drug products, primarily for the United States market. Manufacturing operations are based in the United States and Israel. Perrigo’s portfolio focuses on complex, high-barrier ophthalmological, topical foam and or! al liquid! formulations. Its products include Acetylcysteine Injection 200 mg/mL (6g/30mL), Acetylcysteine Injection 6 g/30 mL (200 mg/1 mL), NOVAPLUS, ACTIDOSE with SORBITOL, ACTIDOSE-AQUA, ASPIRIN SUPPOSITORIES USP, Bacitracin Ophthalmic Ointment USP, Belladonna and Opium Suppositories C-II, BENZOIN COMPOUND TINCTURE USP, Benzoyl Peroxide 10% Acne Medication Wash, CLOBETASOL PROPIONATE LOTION 0.05% and Docusate Sodium.

Active Pharmaceutical Ingredients

Primarily through the Company’s Israel-based business, Perrigo develops, manufactures and markets the complex chemicals and active pharmaceutical ingredients used worldwide by the generic drug industry. Certain of these ingredients are also used in Perrigo’s own pharmaceutical products. It manufactures API at facilities in Israel, India and China. Perrigo API specializes in tailor-made research and process development of APIs and Finished Dosage Forms (FDFs).

Life Sciences

T hrough the Company’s Israel-based business, Perrigo markets and manufactures branded prescription drugs and medical diagnostic products through exclusive agreements with pharmaceutical companies. Its Pharmaceutical and Medical Diagnostic Products businesses also market and manufacture branded prescription drugs under licenses. Other pharmaceutical and medical diagnostics products are imported to Israel through exclusive agreements. Products in life sciences segment include TYSABRI and ELND005. TYSABRI (natalizumab) is indicated for treatment of: Multiple Sclerosis: as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. TYSABRI is recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate MS therapy; Crohn’s Disease (CD): Inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn’s disease with e! vidence o! f inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of tumor necrosis factor-α.

Other

Perrigo’s Pharmaceutical and Medical Diagnostic Products business markets and manufactures branded prescription drugs under licenses. Other pharmaceutical and medical diagnostic products are imported to Israel through exclusive agreements with pharmaceutical and diagnostics companies. This business is divided into two departments: Pharma-Israel and Tayco Diagnostics. Pharma-Israel operates in the Israeli market as a partner in the marketing, sales and distribution of Rx (dermatology, gastroenterology, blood products, CNS, urology and other fields), OTC, generics, branded generics, dermo-cosmetics and dietary supplements. Tayco, the diagnostics division of Perrigo-Israel Pharmaceuticals Ltd., specializes in marketing and sales of medical laboratory systems, reagents, accessories and consumables. It also markets self-monitoring medical devices for diagnosis and treatment of diabetes. The division operates throughout Israel to service the central laboratory, hospital, clinic, point of care and self-testing markets. Its activities in the medical and research fields in Israel cover all market segments: medical (private and public health services), research institutions and the biotech industry.

The Company competes with Dr. Reddy’s Laboratories, Ltd., Actavis Inc., Aaron Industries, Inc., Ohm Laboratories, Inc., PL Developments, LNK International, Inc., Abbott Laboratories, Mead Johnson Nutrition Co., Nestle S.A. (Gerber), Danone Baby Nutrition, Bayer AG, Pfizer, Inc., Rexall Sundown, Inc., Apotex, Glenmark Generics Inc., Impax, Prasco, Sandoz, Taro Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Triax Pharmaceuticals, and Zydus Pharmaceuticals.

Advisors’ Opinion:

  • [By Benjamin Shepherd]

    When you have a run-of-the-mill headache or cold, you take an aspirin or an antihistamine which you most likely picked up off a shelf at your pharmacy. You don’t see a doctor, you don’t have to talk to the pharmacist and you definitely don’t need a prescription for an over-the-counter (OTC) medication, some of which you might even take on a daily basis.

    According to a paper from the American College of Preventative Medicine released in 2011, more than $17 billion of OTC products were sold in 2010 and more than a third of American adults reported using OTC medication on a regular basis. A survey conducted in 1999 showed that nearly 20 percent of the population used an OTC pain medication in any given week.

    While there is the risk that readily available medications may be misused, OTC products are commonly used because they allow fast and direct access to effective medication for a whole host of common ailments. They also have the added benefit of helping to reduce the pressure on our health care system by preventing needless doctor calls.

    When you think of OTC medications many of the first to come to mind, such as Tylenol, Sudafed and Benadryl, are products made by Johnson & Johnson (NYSE: JNJ). But over the past decade – especially since the turmoil of the Great Recession – there has been a rise in “generic generics,” otherwise known as store brands.

    Most OTC medications have been around for decades, in the case of aspirin more than a century, and as a result have virtually no patent protections. That means that competition in the space has always been fierce and most manufacturers invest heavily in building up brand reputation for effectiveness, making it a relatively low margin business to begin with.

    The market has become even more competitive since retailers have realized that they can keep more money in their own pockets by contracting for the production of virtually identical products which can be sold un

  • [By Laura Brodbeck]

    Stocks moving in the Premarket included:

    Boeing(NYSE: BA) lost 1.98 percent in premarket trade after falling 0.25 percent on Friday. Alcoa(NYSE: AA) fell 1.32 percent in premarket trade after gaining 3.58 percent last week. Perrigo Company PLC (NYSE: PRGO) gained 0.36 percent in premarket trade after rising 0.36 percent on Friday. Berkshire HathawayInc (NASDAQ: BRKB) gained 0.27 percent in premarket trade after increasing 5.95 percent last week.

    Earnings

  • [By Holly LaFon]

    During the quarter, Perrigo (PRGO) announced strong September quarter adjusted earnings growth of 20%.  We say “adjusted” because the Company incurred what we believe are non-recurring charges related to the recent purchase of Elan Corporation, which is a branded-drug company domiciled in Ireland.  Upon the closing of this purchase, Perrigo has “re-domiciled” itself in Ireland, with an effective tax rate meaningfully below what they were subjected to in the U.S.  Given that the Company actively pursues a strategy of inorganic growth as much as it pursues organic growth – having acquired six new businesses over the past 18 months (including Elan) – we expect that this new tax structure should make future acquisitions, particularly those U.S. based businesses, much more attractive.  Further, Perrigo’s core business, which includes private-label over-the-counter (OTC) pharmaceuticals and infant formula, drove much of the year-over-year growth.  The Company’s unrivaled scale in manufacturing and marketing of store-branded offerings continues to enable retailers to mimic the value proposition of OTC pharmaceuticals and infant formula.  This “store-brand conversion” is a multi-year trend that we expect will continue for the foreseeable future as consumers continue to become more value-conscious, yet more comfortable with store-brand quality that Perrigo helps engineer. 

  • [By Johnson Research Group]

    Expect to see the shorts’ resolve start to break as CERN stock cracks the $60 level, sparking a short squeeze.

    Short Squeeze Candidate #2: Perrigo (PRGO)

    Click to Enlarge Another classic setup for a short squeeze is the activity that we’re seeing in Perrigo (PRGO).

5 Best Mid Cap Stocks To Own For 2015: Wacker Chemie AG (WCH)

Wacker Chemie AG is a Germany-based company engaged in chemical industry. The Company operates through four business segments: WACKER SILICONES, which produces silicone products, ranging from silanes through silicone fluids, emulsions, elastomers, sealants and resins to pyrogenic silicas; WACKER POLYMERS, which offers a range of polymeric binders and additives; WACKER POLYSILICON, which provides polysilicon, and WACKER BIOSOLUTIONS, which is the life science division of the Company, offers solutions and products for the food, pharmaceutical and agrochemical industries. The Company offers its products for a range of sectors, including consumer goods, food, pharmaceuticals, textiles and the solar, electrical/electronics, basic-chemical industries, medical technology, biotech and mechanical engineering, automotive and construction. The Company also supplies silicon wafers to the semiconductor industry. Advisors’ Opinion:

  • [By Jonathan Morgan]

    Wacker Chemie AG (WCH), the fourth-largest producer of polysilicon, jumped 9 percent to 56.22 euros, its largest increase since December.

    Banks Decline

    Commerzbank slumped 3.7 percent to 8.18 euros, for the biggest loss on the benchmark index.